Astellas Pharma (TSE:4503) Cyclically Adjusted Book per Share: 円836.80 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4503 Astellas Pharma Inc TSE:4503
82 GF Score
Price 円2,151.00
GF Value 円2,227.27
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Cyclically Adjusted Book per Share?

Astellas Pharma TSE:4503 +0.14% 82 Cyclically Adjusted Book per Share is 円836.80 as of Mar. 2026. GuruFocus rates TSE:4503 with a GF Score™ of 82/100 and a GF Value™ of 円2,227.27 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Astellas Pharma's adjusted book value per share for the three months ended in Mar. 2026 was 円1,020.961. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is 円836.80 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Astellas Pharma's average Cyclically Adjusted Book Growth Rate was 4.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 5.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Astellas Pharma was 7.40% per year. The lowest was 4.00% per year. And the median was 5.90% per year.

As of today (2026-07-20), Astellas Pharma's current stock price is 円2151.00. Astellas Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was 円836.80. Astellas Pharma's Cyclically Adjusted PB Ratio of today is 2.57.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Astellas Pharma was 3.62. The lowest was 1.58. And the median was 2.78.


Astellas Pharma  (TSE:4503) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Astellas Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2151.00/836.80
=2.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Astellas Pharma was 3.62. The lowest was 1.58. And the median was 2.78.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Astellas Pharma Cyclically Adjusted Book per Share Related Terms


Astellas Pharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Cyclically Adjusted Book per Share Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 647.57 704.85 753.39 801.64 836.80

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 801.64 809.09 816.31 830.54 836.80

TSE:4503 vs LLY, JNJ, ABBV: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted PB Ratio falls into.


TSE:4503
82GF Score
Astellas Pharma Inc TSE:4503
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1020.961/112.7000*112.7000
=1,020.961

Current CPI (Mar. 2026) = 112.7000.

Astellas Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 578.775 98.100 664.913
201609 596.629 98.000 686.123
201612 638.583 98.400 731.385
201703 615.887 98.100 707.548
201706 666.489 98.500 762.572
201709 665.254 98.800 758.847
201712 677.687 99.400 768.363
201803 641.376 99.200 728.660
201806 650.508 99.200 739.035
201809 667.321 99.900 752.824
201812 672.276 99.700 759.935
201903 667.288 99.700 754.296
201906 662.209 99.800 747.805
201909 686.810 100.100 773.262
201912 705.511 100.500 791.155
202003 694.030 100.300 779.832
202006 703.460 99.900 793.593
202009 715.812 99.900 807.528
202012 736.797 99.300 836.224
202103 748.026 99.900 843.869
202106 746.274 99.500 845.277
202109 765.029 100.100 861.326
202112 791.294 100.100 890.897
202203 799.260 101.100 890.965
202206 842.358 101.800 932.552
202209 902.819 103.100 986.884
202212 859.529 104.100 930.537
202303 839.261 104.400 905.984
202306 878.478 105.200 941.107
202309 912.388 106.200 968.231
202312 838.409 106.800 884.726
202403 890.071 107.200 935.737
202406 936.633 108.200 975.587
202409 854.727 108.900 884.552
202412 834.474 110.700 849.550
202503 845.247 111.100 857.420
202506 827.295 111.700 834.701
202509 900.186 112.000 905.812
202512 984.209 113.000 981.596
202603 1,020.961 112.700 1,020.961

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of 円836.80 mean?
Astellas Pharma (TSE:4503) has a Cyclically Adjusted Book per Share of 円836.80 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Cyclically Adjusted Book per Share too high?
Astellas Pharma's current Cyclically Adjusted Book per Share is 円836.80. Overall, Astellas Pharma has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Cyclically Adjusted Book per Share compare to LLY and JNJ?
Astellas Pharma's Cyclically Adjusted Book per Share of 円836.80 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Cyclically Adjusted Book per Share is 円836.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (TSE:4503) is currently considered Fairly Valued. The stock's GF Value™ is 円2,227.27, compared to a current price of 円2,151.00 — trading 3.4% below its estimated fair value. The current Cyclically Adjusted Book per Share is 円836.80. Astellas Pharma's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Astellas Pharma (TSE:4503), the current Cyclically Adjusted Book per Share is 円836.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (TSE:4503) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of 円2,151.00 is trading 3.4% below its estimated GF Value™ of 円2,227.27. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for TSE:4503:

  • Cyclically Adjusted Book per Share: 円836.80
  • GF Value™: 円2,227.27 vs. price of 円2,151.00 (3.4% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the TSE:4503 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
82GF Score

Get the complete analysis for TSE:4503

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,151.00
Price
円2,227.27
GF Value